BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:AND017 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of AND017\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06304103-899@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:AND017: Phase 2 readout est. (NCT06304103)
DESCRIPTION:AND017\, phase 2\, Myelodysplastic Syndromes.\nStudy: A Study o
 f Efficacy and Safety of AND017 in Patients With Myelodysplastic Syndrome\
 nEstimated primary completion: December 2026. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/and017#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06304103
URL:https://assetmemo.bio/drug/and017#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06302491-899@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:AND017: Phase 2 readout est. (NCT06302491)
DESCRIPTION:AND017\, phase 2.\nStudy: A Study of Safety and Efficiency of A
 ND017 in Patients With β-thalassemia\nEstimated primary completion: Decem
 ber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/and017#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06302491
URL:https://assetmemo.bio/drug/and017#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07494409-899@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20270220
DTEND;VALUE=DATE:20270221
SUMMARY:AND017: Phase 3 readout est. (NCT07494409)
DESCRIPTION:AND017\, phase 3\, Chronic Kidney Disease.\nStudy: A Study of A
 ND017 to Evaluate Efficacy and Safety in Dialysis-Dependent Chronic Kidney
  Disease (DD-CKD) Patients With Anemia\nEstimated primary completion: 20 F
 ebruary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/and017#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0749
 4409
URL:https://assetmemo.bio/drug/and017#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07487727-899@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:AND017: Phase 3 readout est. (NCT07487727)
DESCRIPTION:AND017\, phase 3\, Chronic Kidney Disease.\nStudy: A Study of A
 ND017 to Evaluate Efficacy and Safety in Patients With Anemia Due to Non-D
 ialysis-Dependent Chronic Kidney Disease (NDD-CKD)\nEstimated primary comp
 letion: 1 March 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /and017#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07487727
URL:https://assetmemo.bio/drug/and017#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06075030-899@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:AND017: Phase 2 readout est. (NCT06075030)
DESCRIPTION:AND017\, phase 2.\nStudy: A Study of AND017 in Cancer Related A
 nemic Patients Receiving Chemotherapy\nEstimated primary completion: Decem
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/and017#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06075030
URL:https://assetmemo.bio/drug/and017#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06075043-899@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:AND017: Phase 2 readout est. (NCT06075043)
DESCRIPTION:AND017\, phase 2.\nStudy: A Study of AND017 to Treat Cancer Rel
 ated Anemia in Patients Not Receiving Chemotherapy\nEstimated primary comp
 letion: May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/and
 017#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06075043
URL:https://assetmemo.bio/drug/and017#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
